Sharemaestro company-news research for Pasithea Therapeutics Corp (KTTA), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest KTTA news and sentiment

Pasithea Therapeutics Corp

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
30-day score50Neutral is 50
Early balanced news score 15/100 evidence confidence 100% direct company focus 7 current stories across 2 publishers
Latest weekly closeUSD 0.58week of 4 Sep 2026
Main news subjectMarket update72/100 share of current news
News data statusPartial9 duplicate stories removed

Current company news

Early balanced news score

7 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone41/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences Investing News Network · 04 Sep 2026 00:38

What supports the score

Direct evidence

7 current stories are mapped specifically to KTTA.

What limits the score

Source breadth

Only 2 publishers currently contribute to the measured read.

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.006.

Confidence

Confidence is 15/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
15/100
Confidencethin evidence
100%/100
Company news7 company stories
98/100
Story agreement2/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
13 Aug: 1 stories14 Aug: 1 stories15 Aug: 1 stories19 Aug: 1 stories21 Aug: 2 stories04 Sep: 1 stories 13 Aug: tone 43, 1 stories14 Aug: tone 50, 1 stories15 Aug: tone 39, 1 stories19 Aug: tone 50, 1 stories21 Aug: tone 50, 2 stories04 Sep: tone 50, 1 stories 95505
13 Aug28 Aug11 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence0
0.006 after freshness weighting
Source breadth40
2 independent publishers
Company relevance100
share tied directly to this company
Freshness10
recency-weighted evidence
Agreement98
how closely stories agree
Publisher mix46
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks11 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Mar 2026: close 0.82, indexed 100.020 Mar 2026: close 0.797, indexed 97.227 Mar 2026: close 0.74, indexed 90.203 Apr 2026: close 0.7699, indexed 93.910 Apr 2026: close 0.7, indexed 85.417 Apr 2026: close 0.7424, indexed 90.524 Apr 2026: close 0.69, indexed 84.101 May 2026: close 0.841, indexed 102.608 May 2026: close 0.7953, indexed 97.015 May 2026: close 0.7801, indexed 95.122 May 2026: close 0.6998, indexed 85.329 May 2026: close 0.7153, indexed 87.205 Jun 2026: close 0.585, indexed 71.312 Jun 2026: close 0.5911, indexed 72.119 Jun 2026: close 0.5, indexed 61.026 Jun 2026: close 0.5434, indexed 66.303 Jul 2026: close 0.5498, indexed 67.010 Jul 2026: close 0.4924, indexed 60.017 Jul 2026: close 0.45, indexed 54.924 Jul 2026: close 0.455, indexed 55.531 Jul 2026: close 0.4599, indexed 56.107 Aug 2026: close 0.5067, indexed 61.814 Aug 2026: close 0.4805, indexed 58.621 Aug 2026: close 0.5394, indexed 65.828 Aug 2026: close 0.56, indexed 68.304 Sep 2026: close 0.58, indexed 70.7 26 Jun 2026: news score 50, close 0.5434, 4 stories5003 Jul 2026: news score 50, close 0.5498, 6 stories10 Jul 2026: news score 50, close 0.4924, 8 stories5017 Jul 2026: news score 50, close 0.45, 9 stories24 Jul 2026: news score 55, close 0.455, 13 stories5531 Jul 2026: news score 51, close 0.4599, 20 stories07 Aug 2026: news score 51, close 0.5067, 21 stories5114 Aug 2026: news score 50, close 0.4805, 23 stories21 Aug 2026: news score 49, close 0.5394, 23 stories4928 Aug 2026: news score 50, close 0.56, 11 stories04 Sep 2026: news score 50, close 0.58, 10 stories50 Price index 108.3 78.7 49.2 News score 100 50 0
13 Mar09 Jun04 Sep
Weekly close, indexedSentiment score
26-week price-29.3%latest close 0.58
News score change+0first to latest comparable week
One-week response+3.6%Price confirming higher
Fair-value position-81.6%Below fair value
WeekNews scoreCloseWeekly move
04 Sep 202650USD 0.58+3.6%
28 Aug 202650USD 0.56+3.8%
21 Aug 202649USD 0.5394+12.3%
14 Aug 202650USD 0.4805-5.2%
07 Aug 202651USD 0.5067+10.2%
31 Jul 202651USD 0.4599+1.1%
24 Jul 202655USD 0.455+1.1%
17 Jul 202650USD 0.45-8.6%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update504 stories · 57%
Earnings443 stories · 43%

Source mix

Where the evidence comes from

46/100 independence
TradingView392 stories · 29%
Stock Titan502 stories · 29%
vinanet.vn431 stories · 14%
Investing News Network501 stories · 14%
Vinanet501 stories · 14%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences4Financial Markets3Finance3Earnings1

Earlier readings

How the score has changed

29 comparable readings · 80 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+050 to 50 · Broadly stable
Observed range49–5550 is the neutral baseline
Evidence depth7stories at latest stored reading · +5
Confidence14/100Provisional · +14
22 Jun50 neutral11 Sep 04:06
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
11 Sep 04:0650+014/100 (-1)7 (-3)Provisional
04 Sep 23:5950+115/100 (-5)10 (-13)Provisional
21 Aug 23:5949+020/100 (-2)23 (-1)Provisional
19 Aug 23:5949+022/100 (-6)24 (0)Provisional
15 Aug 23:5949-128/100 (+3)24 (+1)Provisional
14 Aug 23:5950+025/100 (-1)23 (+1)Provisional
13 Aug 23:5950-126/100 (+8)22 (0)Provisional
11 Aug 23:5951+018/100 (-5)22 (0)Provisional

Source headlines

The news behind the score

Showing 1-7 of 7

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
Investing News NetworkDirect company coverageStored article

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

Pasithea Therapeutics (NASDAQ: KTTA) announced its participation in two investor conferences in September 2026: the 12th Annual Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Management will hold one-on-one meetings and present on its lead drug candidate, PAS-004, a next-generation MEK inhibitor currently in Phase 1 clinical trials for advanced cancer and NF1-associated plexiform neurofibromas.

FinanceLife Sciences
Published
04 Sep 2026 00:38
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.1d old
Duplicates
3 consolidated
#2—Not directional
Stock TitanDirect company coverageStored article

Pasithea (NASDAQ: KTTA) gets Nasdaq reprieve before possible delisting

Pasithea Therapeutics Corp. (NASDAQ: KTTA) has received an additional 180-day extension from Nasdaq, pushing its compliance deadline to February 16, 2027, to meet the $1.00 minimum bid price requirement. The company was initially notified of non-compliance on February 20, 2026, and its initial grace period was set to expire on August 19, 2026. Pasithea may consider a reverse stock split to regain compliance, and failure to do so could lead to delisting proceedings.

Financial MarketsLife Sciences
Published
21 Aug 2026 21:11
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 20.3d old
Duplicates
2 consolidated
#3—Not directional
TradingViewDirect company coverageStored article

Pasithea Therapeutics Received Notice of Noncompliance

Pasithea Therapeutics (KTTA) received a notice of noncompliance from Nasdaq due to its stock price falling below the $1.00 minimum bid requirement. Nasdaq granted the company a 180-day extension until February 16, 2027, to regain compliance, with a reverse stock split being a potential action. Failure to comply could lead to delisting.

FinanceFinancial Markets
Published
21 Aug 2026 21:11
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 20.3d old
Duplicates
1 consolidated
#4—Not directional
VinanetDirect company coverageScored from headline

Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest Reading - Low Growth Earnings

Published
19 Aug 2026 18:47
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 22.4d old
Duplicates
1 consolidated
#539Tone
TradingViewDirect company coverageStored article

Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary

Pasithea Therapeutics Corp. reported a Q2 2026 net loss of $(5.27M) and diluted EPS of $(0.16), marking a wider loss compared to the previous year. The company is advancing its PAS-004 clinical development programs, with a significant increase in R&D expenses. Pasithea has refocused its pipeline on PAS-004 and discovery-stage PAS-001, discontinuing PAS-003.

EarningsLife Sciences
Published
15 Aug 2026 00:12
News subject
Earnings
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 39/100
30-day weight
63.8% of the score · 27.2d old
Duplicates
1 consolidated
#6—Not directional
Stock TitanDirect company coverageStored article

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock

Vivo Opportunity entities, including Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., have reported beneficial ownership of 9.99% of Pasithea Therapeutics (KTTA) common stock. These holdings comprise a mix of common shares and pre-funded warrants, which include provisions to prevent ownership exceeding 9.99%. The ownership percentages are based on 33,414,448 shares outstanding as of May 13, 2026.

FinanceFinancial MarketsLife Sciences
Published
14 Aug 2026 20:32
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 27.3d old
Duplicates
1 consolidated

Earlier company news

KTTA news archive

31 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 31 older KTTA headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

5 not scored

A news provider linked these stories to KTTA, but the headline and available text are not mainly about Pasithea Therapeutics Corp. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of KTTA sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context